All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
#IMS2024: Relapsed/refractory multiple myeloma
Bookmark this article
To update you on the exciting content presented at the 21st International Myeloma Society (IMS) Annual Meeting, we have collated our social media coverage. Catch up with our live social media posts relating to relapsed/refractory multiple myeloma here.
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 30, 2024
Hermann Einsele @H_Einsele discusses T-cell exhaustion as a physiological process to prevent excessive T-cell responses, and strategies to overcome this process which currently limits the efficacy of T-cell engaging therapies in MM.
Einsele… pic.twitter.com/WADJ0tSwe9
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 30, 2024
Paola Neri discusses mechanisms of resistance to CAR-T and BsAbs, highlighting that acquired resistance to T-cell based therapies is predominantly driven by target antigenic loss post BCMA or GPRC5D TCE (+++) and CAR-T (+).
Follow our live… pic.twitter.com/2nVxRBKMX8
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 30, 2024
Joanna Opalinska discusses the optimization of BCMA targeting with ADCs.
Opalinska explores the rationale behind BCMA targeting with a focus on belantamab mafodotin MoA and trial data, highlighting the statistically significant and clinically… pic.twitter.com/EGgFjvHr4S
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 30, 2024
Jordan Schecter @MyelomaRnD explores the rationale behind and data supporting the use of trispecific antibodies in RRMM.
Schecter highlights the need for new treatments to overcome resistance and provide clinical benefit following disease… pic.twitter.com/Lw0uSPt2N9
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 30, 2024
Suzanne Trudel shares results from the phase III DREAMM-8 study of belantamab mafodotin + pomalidomide + dexamethasone (BPd) vs pomalidomide + bortezomib + dexamethasone (PVd) in patients with RRMM (N=302).
BPd produced a significant survival… pic.twitter.com/AnZHmhw1Q7
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 30, 2024
Cyrille Touzeau shares findings from the IFM phase II I2D study investigating the oral triplet iberdomide + ixazomib + dexamethasone in elderly patients with MM at first relapse (N=70).
The ORR was 65%, with a ≥ VGPR of 36%. The 12-month PFS… pic.twitter.com/DkkjdifoYz
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 30, 2024
Abel Costa @anetoc shares findings from a trial of sonrotoclax + dexamethasone in patients with RRMM harboring t(11;14) mutations (N=32).
The ORR was 75% among 24 efficacy-evaluable patients, with a ≥ VGPR of 50%. The combination was well… pic.twitter.com/x1oU8TWLJP
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 30, 2024
Shebli Atrash @AtrashShebli shares findings a phase I trial of belantamab mafadotin (Belantamab) combined with carfilzomib, lenalidomide, and dexamethasone (KRd) for MM after one prior line of therapy (LOT) (N=19).
The MTD of Belantamab was… pic.twitter.com/AiYSGpXPOB
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 30, 2024
Luciano Costa @End_myeloma shares preliminary results from Cohort A of the phase I dose-finding CA057-003 trial of mezigdomide (MEZI), tazemetostat (TAZ), and dexamethasone (DEX) in patients with RRMM (N=15).
The ORR was 53.3% across all doses… pic.twitter.com/ArCxTLbQB1
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 30, 2024
Neha Korde @kordeneha1 shares findings from a study of maintenance therapy cessation for MM patients with 3-year sustained MRD negative remissions (N=46).
The MRD negative rate at 1 year of stopping therapy was 85%, with an MRD negative… pic.twitter.com/dUS3Fzlh96
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 30, 2024
Meletios Dimopoulos @thanosdimop shares patient-reported outcomes from the phase III DREAMM-8 trial comparing belantamab mafodotin, pomalidomide, and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd) in patients with RRMM… pic.twitter.com/w3LT7NTpch
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 29, 2024
Andrew Spencer shares interim findings from a phase II study of of durcabtagene autoleucel (PHE885), a BCMA-directed CAR-T cell therapy in patients with RRMM (N=161 enrolled, N=145 infused).
Durcabtagene autoleucel produced high response rates… pic.twitter.com/rZXgJjyuyO
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 29, 2024
Doris Hansen presents findings from a multicenter retrospective comparison study of SOC ide-cel vs cilta-cel CAR T-cell therapy in RRMM (N=641).
Cilta-cel demonstrated higher efficacy in terms of responses, survival overall, and survival by… pic.twitter.com/rYUQFgOuz9
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 29, 2024
María-Victoria Mateos @mvmateos shares a study update from the phase III CARTITUDE-4 trial comparing cilta-cel with SOC in lenalidomide (Len)-refractory MM (N=419 randomized; N=176 received cilta-cel as study tx).
Cilta-cel significantly… pic.twitter.com/MJnp7Uqe5X
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 28, 2024
Marc Raab @RaabMarc shares findings from a first in human trial of the anti-BCMA antibody-drug conjugate HDP-101 in RRMM (N=18).
HDP-101-01 demonstrated a manageable safety profile and significant efficacy at a dose of 100 mg/Kg, with an ORR… pic.twitter.com/gF9nXfisQY
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 28, 2024
Yael Cohen shares findings from a phase I trial investigating the efficacy and safety of HBI0101, an anti-BCMA CAR-T, for RRMM (N=84).
The ORR was 92% with a CR/sCR rate of 55%, and 74% of patients achieving MRD negativity. The median PFS was… pic.twitter.com/mG10ThPHdA
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 28, 2024
Myo Htut shares safety and preliminary efficacy findings from a phase I study of of BMS-986393, a GPRC5D CAR-T cell therapy, in patients with RRMM and 1–3 prior regimens (N=31).
After a median follow-up of 4.9 months, a single infusion of… pic.twitter.com/ZTEynsImXV
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 28, 2024
Yael Cohen shares updated phase IB results with >1 year of follow-up from the RedirecTT-1 study which investigated talquetamab (Tal) + teclistamab (Tec) in patients with RRMM (all doses N=94, RP2R n=44).
Tal + Tec produced deep and durable… pic.twitter.com/wNvvNbKGdQ
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 28, 2024
Nizar Bahlis @NBahlis shares findings from the phase Ib TRIMM-2 study investigating the efficacy and safety of talquetamab (Tal) + daratumumab (Dara) + pomalidomide (Pom) in patients with RRMM (Tal 0.4 mg/Kg QW n=18; Tal 0.8 mg/Kg Q2W n=59).… pic.twitter.com/vM4BJ6MQ4j
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 28, 2024
Surbhi Sidana @SurbhiSidanaMD shares findings from real world experience with updated follow-up of the safety and efficacy of SOC cilta-cel for RRMM (N = 255, with N = 236 proceeding to cilta-cel infusion).
Response rates to cilta-cel were… pic.twitter.com/ZcndjnQtac
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 27, 2024
Paula Rodriguez-Otero @paurotero discusses the choice and sequencing of T-cell therapies, with consideration of availability, patient- and disease-related factors, safety profiles, and impacts on sequencing, highlighting the need for improved… pic.twitter.com/p6qdx7VTBh
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 27, 2024
Ajai Chari @AjaiChari provides an update on BCMA/GPRC5D/FcRH5-directed CAR-T cell/BsAb immunotherapies, noting successes to date & ongoing unmet needs.
Chari discusses approved BCMA-directed CAR-T therapies (ide-cel & cilta-cel), those in… pic.twitter.com/YMeRH58Cqf
CONGRESS | #IMS2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 26, 2024
Joy Ho discusses the treatment of RRMM with non-T cell redirected therapies, highlighting the need for effective strategies following multi-agent and multi-class refractoriness.
Anti-CD38 antibody-based triplets (PI/IMiD combinations) are… pic.twitter.com/5pW8C1lnHh
CONGRESS | #IMS2024 | POSTER
— Multiple Myeloma Hub (@MM_Hub) September 25, 2024
Noopur Raje @NoopurRajeMD shares the 5-year follow-up analysis from the phase II KarMMa trial investigating the efficacy and safety of ide-cel in pts with triple-class–exposed (TCE) RRMM (N = 137).
At a median follow-up of 63.6 months ORR was 76.6%,… pic.twitter.com/n97eployPM
CONGRESS | #IMS2024 | POSTER
— Multiple Myeloma Hub (@MM_Hub) September 25, 2024
Beatrice Razzo shares findings from real-world experience with teclistamab for RRMM from the U.S. Myeloma Immunotherapy Consortium (N = 391).
The ORR was 55% and ≥VGPR rate was 45%; comparable to findings from MajesTEC-1.
Follow our live feed for… pic.twitter.com/Pt7HcBO0d5
CONGRESS | #IMS2024 | POSTER
— Multiple Myeloma Hub (@MM_Hub) September 25, 2024
María-Victoria Mateos @mvmateos reviews the design and aims of the phase III KarMMa-9 trial which is currently recruiting (planned N = 618).
The study will assess the efficacy and safety of ide-cel with lenalidomide (R) maintenance vs R maintenance… pic.twitter.com/lxIgamgg17
Your opinion matters
2 votes - 43 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox